GlassScriptPhysician profile
Kruti M Shah
NPI 1891751780
$8,902.86
in general payments reported to CMS, 2019-2025
45 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,544 · 2020: $1,042 · 2021: $1,405 · 2022: $1,419 · 2023: $1,689 · 2024: $1,426 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,473 · Education: $19.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,472.63 |
| Education | $19.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,279.06 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,056.72 | 2019-2025 | Mounjaro, Zepbound, Lyumjev |
| Abbott Laboratories | $722.58 | 2019-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $629.28 | 2019-2025 | Jardiance, Synjardy |
| Corcept Therapeutics | $551.41 | 2019-2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $507.80 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $486.78 | 2019-2025 | Zerbaxa, Steglatro |
| Amgen INC. | $369.92 | 2019-2025 | Prolia, Evenity, Repatha |
| Abbvie INC. | $365.61 | 2019-2025 | Synthroid, Ubrelvy, Qulipta |
| Sanofi-Aventis U.S. LLC | $297.85 | 2019-2024 | |
| Medtronic, INC. | $283.86 | 2022-2025 | Minimed 780g, Minimed 770g |
| Xeris Pharmaceuticals, INC. | $212.52 | 2022-2024 | Gvoke Hypopen, Recorlev |
| Novartis Pharmaceuticals Corporation | $180.69 | 2022-2023 | |
| Amarin Pharma, INC. | $165.63 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $154.06 | 2023-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kruti Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.